Dent Neurologic Institute   Report issue

Academic/Hospital Phase 2 Phase 3 Phase 4
Founded: Amherst NY United States (1963)

Organization Overview

First Clinical Trial
2010
NCT00893594
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Dent Neurologic Institute

Active Ingredients

Drugs in Phase 4 Trials (1)

diphenhydramine (benadryl) (1 trial)

Drugs in Phase 3 Trials (1)

lamotrigine (lamictal) (2 trials)

Drugs in Phase 2 Trials (5)

bupropion (wellbutrin) (1 trial)

corticotropin (acthar) (1 trial)

lucanthone (1 trial)

primidone (mysoline) (1 trial)

temozolomide (temodar) (1 trial)

Drugs in Other Trials (2)

naproxen (naprosyn) (1 trial)

sumatriptan (zecuity) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Dizziness (Phase 3)

Glioblastoma (Phase 2)

Meniere Disease (Phase 3)

Migraine Disorders (Phase 2)

Neoplasm Metastasis (Phase 2)

Vertigo (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 7
  • # of Trial APIs: 9